All
Nubeqa Outperforms Xtandi, Erleada in Non-metastatic Castration-resistant Prostate Cancer
February 16th 2023Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ASCO GU.